Marker Therapeutics Inc (MRKR)

$1.43 -0.01 (-0.69%)
Market Cap 24.18M
Revenue (ttm) 3.55M
Net Income (ttm) -12.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -342.54%
Debt to Equity Ratio 0.00
Volume 52,800
Avg Vol 120,846
Day's Range N/A - N/A
Shares Out 16.67M
Stochastic %K 16%
Beta 1.43
Analysts Strong Sell
Price Target $7.87

Company Profile

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 400 6400
Address:
2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, United States
SinglesOverHomeRun
SinglesOverHomeRun May. 8 at 3:49 AM
$MRKR recently?
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 7 at 6:40 PM
⏳️ Potential swing ideas 💡💡 ✅️ $MRKR recently announced positive APOLLO study, recently partnered with Cellpont for MT-601 Manufacturing, company focuses on developing novel T-cell therapies for hematological malignancies and solid tumors, HC Wainwright price target $10, WBB Securities price target $12.50, Canaccord Genuity buy rating price target $8.X, Brookline buy rating ✅️ $INAB previously announced patient 009 in phase 1 trial of INB-200 for newly-diagnosed (glioblastoma multiforme) GBM has reached a significant clinical milestone, achieving a 4-year remission, which far surpasses the progression-free outcomes observed in other clinical trials involving IDH-mutant glioma patients, Soumit Roy buy rating, analyst strong boy rating, HC Wainwright price target $6, company focuses on advancing gamma-delta (γδ) T cell-based therapies targeting cancer and autoimmune diseases
0 · Reply
seanolbrych
seanolbrych May. 7 at 2:24 PM
$MRKR
0 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 3:00 PM
$MRKR
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 4 at 9:12 PM
$MRKR RSI: 47.46, MACD: 0.0047 Vol: 0.12, MA20: 1.55, MA50: 1.45 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
itzik4ever
itzik4ever May. 3 at 6:50 PM
$SLS $SLS $MRKR $SLS $MRKR This guy is a clown. Even his profile pic is fake.
4 · Reply
BioRich
BioRich May. 3 at 6:48 PM
$SLS Biggest difference between me and most of the PermaPumpers on this board... I think like the regulators, they think like hopeful gamblers Where I look at all sides and questions EVERYTHING, most Rope Hats only look for or acknowledge information that benefits their fragile narrative. As I like to share on other boards (and do myself), evaluate $SLS current situation and reality as one of their competitors. If $MRKR had the EXACT same situation as $SLS does right now, would you be pumping $MRKR? Or would you find holes in their narrative. Emotional hope can blur reality. Don't forget that.
1 · Reply
itsMeRich
itsMeRich Apr. 30 at 7:43 PM
$MRKR Last post: Hey Marker Management: No one cares anymore, mainly due to your lack of communication and correspondence.
1 · Reply
itsMeRich
itsMeRich Apr. 30 at 7:38 PM
$MRKR Hey Marker Management: You want our yes votes? Change your compensation structure from one of a salary- to one that compensates you with the company’s shares! Then we will see if you care about any of us shareholders.
1 · Reply
itsMeRich
itsMeRich Apr. 30 at 7:33 PM
$MRKR PS - Please vote “NO” to the ridiculous request to add 100,000,000 authorized shares to the current amount.
0 · Reply
Latest News on MRKR
Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)

2026-03-18T21:35:16.000Z - 2 months ago

Marker Therapeutics reports FY25 EPS (79c), two estimates (94c)

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Mar 18, 2026, 5:31 PM EDT - 2 months ago

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Marker Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 25, 2026, 8:00 AM EST - 2 months ago

Marker Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 8:00 AM EST - 3 months ago

Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Marker announces Baylor’s TACTOPS study featured on Good Morning America

2026-01-26T12:15:08.000Z - 3 months ago

Marker announces Baylor’s TACTOPS study featured on Good Morning America

Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer

2026-01-05T12:25:31.000Z - 4 months ago

Marker Therapeutics announces publication on MAR-T cells in pancreatic cancer

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Jan 5, 2026, 7:00 AM EST - 4 months ago

Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer

Marker Therapeutics initiated with a Buy at H.C. Wainwright

2025-12-08T13:30:08.000Z - 5 months ago

Marker Therapeutics initiated with a Buy at H.C. Wainwright

Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year

2025-11-14T12:05:51.000Z - 6 months ago

Marker Therapeutics reports Q3 EPS (12c) vs (26c) last year

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Nov 14, 2025, 7:00 AM EST - 6 months ago

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

Marker Therapeutics appoints Penkus Corzo to board of directors

2025-11-05T12:50:27.000Z - 6 months ago

Marker Therapeutics appoints Penkus Corzo to board of directors

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Nov 5, 2025, 7:30 AM EST - 6 months ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Nov 3, 2025, 9:15 AM EST - 6 months ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Marker Therapeutics announces first patient treated in off-the-shelf program

2025-10-06T11:40:46.000Z - 7 months ago

Marker Therapeutics announces first patient treated in off-the-shelf program

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Oct 6, 2025, 7:30 AM EDT - 7 months ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Marker Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 10, 2025, 12:30 PM EDT - 8 months ago

Marker Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 28, 2025, 8:00 AM EDT - 9 months ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Marker Therapeutics Transcript: Study Update

Aug 26, 2025, 8:30 AM EDT - 9 months ago

Marker Therapeutics Transcript: Study Update

Marker Therapeutics provides update on observations from Phase 1 APOLLO study

2025-08-26T11:11:07.000Z - 9 months ago

Marker Therapeutics provides update on observations from Phase 1 APOLLO study

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Aug 26, 2025, 7:00 AM EDT - 9 months ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Marker Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 12:30 PM EDT - 9 months ago

Marker Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Jul 30, 2025, 8:00 AM EDT - 10 months ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601

2025-06-17T12:11:26.000Z - 11 months ago

Marker, Cellpoint announce collaboration for cGMP manufacturing of MT-601

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Jun 17, 2025, 8:00 AM EDT - 11 months ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

Marker Therapeutics reports evidence from Phase 1 APOLLO study

2025-05-20T12:15:28.000Z - 1 year ago

Marker Therapeutics reports evidence from Phase 1 APOLLO study

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

May 20, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

May 19, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

2025-03-31T12:50:08.000Z - 1 year ago

Marker Therapeutics reports FY24 EPS ($1.19) vs ($1.59) last year

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Mar 31, 2025, 8:45 AM EDT - 1 year ago

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Marker Therapeutics initiated with a Buy at Canaccord

2025-03-05T11:32:28.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Canaccord

Marker Therapeutics initiated with a Buy at Canaccord

2025-03-05T10:17:01.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Canaccord

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Marker Therapeutics initiated with a Buy at Brookline

2025-02-10T23:05:05.000Z - 1 year ago

Marker Therapeutics initiated with a Buy at Brookline

Marker Therapeutics files to sell 10.06M shares of common stock for holders

2025-01-10T22:15:17.000Z - 1 year ago

Marker Therapeutics files to sell 10.06M shares of common stock for holders

Biotech Alert: Searches spiking for these stocks today

2024-12-20T15:50:26.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

ARDX MRK NVO OGI UTHR VKTX

Marker Therapeutics sells 5.03M shares at $3.20 in private placement

2024-12-19T13:25:36.000Z - 1 year ago

Marker Therapeutics sells 5.03M shares at $3.20 in private placement

Marker Therapeutics provides update on MT-601 patients

2024-12-19T13:10:51.000Z - 1 year ago

Marker Therapeutics provides update on MT-601 patients

Marker Therapeutics Announces $16.1 Million Private Placement

Dec 19, 2024, 8:06 AM EST - 1 year ago

Marker Therapeutics Announces $16.1 Million Private Placement

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Dec 19, 2024, 8:05 AM EST - 1 year ago

Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma

Marker Therapeutics awarded $9.5M grant from CPRIT

2024-12-17T12:05:36.000Z - 1 year ago

Marker Therapeutics awarded $9.5M grant from CPRIT

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Dec 17, 2024, 7:00 AM EST - 1 year ago

Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Dec 10, 2024, 8:30 AM EST - 1 year ago

Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium

Marker Therapeutics files $300M mixed securities shelf

2024-11-27T21:30:12.000Z - 1 year ago

Marker Therapeutics files $300M mixed securities shelf

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Nov 26, 2024, 11:00 AM EST - 1 year ago

Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 14, 2024, 4:30 PM EST - 1 year ago

Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 14, 2024, 4:30 PM EDT - 1 year ago

Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin's Lymphoma

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 15, 2024, 4:15 PM EDT - 2 years ago

Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Mar 25, 2024, 5:45 PM EDT - 2 years ago

Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 22, 2024, 12:30 PM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Jan 22, 2024, 7:30 AM EST - 2 years ago

Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Jan 8, 2024, 8:24 AM EST - 2 years ago

Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Dec 21, 2023, 11:00 AM EST - 2 years ago

Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 5:00 PM EST - 2 years ago

Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Aug 17, 2023, 9:03 AM EDT - 2 years ago

Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 14, 2023, 4:30 PM EDT - 2 years ago

Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Marker Therapeutics Transcript: Status Update

Aug 9, 2023, 11:00 AM EDT - 3 years ago

Marker Therapeutics Transcript: Status Update

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

Aug 7, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Jul 10, 2023, 7:00 AM EDT - 3 years ago

European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Jun 26, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Jun 12, 2023, 7:00 AM EDT - 3 years ago

Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

May 31, 2023, 6:30 AM EDT - 3 years ago

Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

May 8, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

May 1, 2023, 7:30 AM EDT - 3 years ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Mar 22, 2023, 8:10 AM EDT - 3 years ago

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Dec 13, 2022, 7:00 AM EST - 3 years ago

Marker Therapeutics and Lincoln Park Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Sep 13, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics Awarded $2 Million Grant from U.S. FDA to Support Marker's Phase 2 ARTEMIS Trial of MT-401 in Post-Transplant AML

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Sep 8, 2022, 7:00 AM EDT - 3 years ago

Marker Therapeutics to Participate in Cantor Fitzgerald Cell and Genetic Medicines Conference

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Aug 11, 2022, 4:22 PM EDT - 4 years ago

Marker Therapeutics Reports Q2 2022 Operating and Financial Results

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Aug 4, 2022, 4:37 PM EDT - 4 years ago

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

May 13, 2022, 7:00 AM EDT - 4 years ago

Marker Therapeutics Reports Q1 2022 Operating and Financial Results

SinglesOverHomeRun
SinglesOverHomeRun May. 8 at 3:49 AM
$MRKR recently?
0 · Reply
PSM_EmpowerTrading
PSM_EmpowerTrading May. 7 at 6:40 PM
⏳️ Potential swing ideas 💡💡 ✅️ $MRKR recently announced positive APOLLO study, recently partnered with Cellpont for MT-601 Manufacturing, company focuses on developing novel T-cell therapies for hematological malignancies and solid tumors, HC Wainwright price target $10, WBB Securities price target $12.50, Canaccord Genuity buy rating price target $8.X, Brookline buy rating ✅️ $INAB previously announced patient 009 in phase 1 trial of INB-200 for newly-diagnosed (glioblastoma multiforme) GBM has reached a significant clinical milestone, achieving a 4-year remission, which far surpasses the progression-free outcomes observed in other clinical trials involving IDH-mutant glioma patients, Soumit Roy buy rating, analyst strong boy rating, HC Wainwright price target $6, company focuses on advancing gamma-delta (γδ) T cell-based therapies targeting cancer and autoimmune diseases
0 · Reply
seanolbrych
seanolbrych May. 7 at 2:24 PM
$MRKR
0 · Reply
SuperGreenToday
SuperGreenToday May. 6 at 3:00 PM
$MRKR
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 4 at 9:12 PM
$MRKR RSI: 47.46, MACD: 0.0047 Vol: 0.12, MA20: 1.55, MA50: 1.45 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
itzik4ever
itzik4ever May. 3 at 6:50 PM
$SLS $SLS $MRKR $SLS $MRKR This guy is a clown. Even his profile pic is fake.
4 · Reply
BioRich
BioRich May. 3 at 6:48 PM
$SLS Biggest difference between me and most of the PermaPumpers on this board... I think like the regulators, they think like hopeful gamblers Where I look at all sides and questions EVERYTHING, most Rope Hats only look for or acknowledge information that benefits their fragile narrative. As I like to share on other boards (and do myself), evaluate $SLS current situation and reality as one of their competitors. If $MRKR had the EXACT same situation as $SLS does right now, would you be pumping $MRKR? Or would you find holes in their narrative. Emotional hope can blur reality. Don't forget that.
1 · Reply
itsMeRich
itsMeRich Apr. 30 at 7:43 PM
$MRKR Last post: Hey Marker Management: No one cares anymore, mainly due to your lack of communication and correspondence.
1 · Reply
itsMeRich
itsMeRich Apr. 30 at 7:38 PM
$MRKR Hey Marker Management: You want our yes votes? Change your compensation structure from one of a salary- to one that compensates you with the company’s shares! Then we will see if you care about any of us shareholders.
1 · Reply
itsMeRich
itsMeRich Apr. 30 at 7:33 PM
$MRKR PS - Please vote “NO” to the ridiculous request to add 100,000,000 authorized shares to the current amount.
0 · Reply
itsMeRich
itsMeRich Apr. 30 at 7:28 PM
$MRKR Anyone know what’s up with Marker actually calling shareholders on the phone, and asking for our vote? While I’m flattered- we surely don’t own enough shares to out vote the larger , institutional holders. They’ve mailed us numerous ballots, and e- mailed as well. I’ve never seen this before. Thanks Marker management- but I’m looking for an exit ramp to sell your shares. So many other biotech companies have shown proven results to their trials- and subsequent approvals- and yet you fail to even issue any updates to your shareholders. Looks like I’ll end up with a big tax loss for my 8 years of waiting as a patient, and disappointed shareholder.
0 · Reply
GoIrish1776
GoIrish1776 Apr. 29 at 2:22 AM
$MRKR I am getting a lot of reminders to vote. Phone calls, letters, text messages. It reminds me of what our lawyers would say when one of our investments was going to do a fundraise at a flat or lower price. Make sure the company offers to every current investor in writing. Less of a case if sued. It makes me suspicious of the 100m share expansion. Dilution is coming. It’s just a question of how bad. Maybe all the insiders can get a fistful of warrants again. This company has really been a disaster. Wolf gave them a sweetheart deal and what did they do? Pissed it away and kicked him to the curb. Joke.
2 · Reply
itsMeRich
itsMeRich Apr. 25 at 11:01 AM
$MRKR this company doesn’t release any news, trial results, or anything to give us shareholders any confidence in them- yet they want us to vote to allow them to increase their authorized shares from 30 million to 130 million- what a joke. I’m sorry I ever got involved with them so many years ago- now I just wish they would sell out to some big pharma company- that I’d vote for. Money wasted- lesson learned.
0 · Reply
GoIrish1776
GoIrish1776 Apr. 20 at 1:08 PM
$MRKR Eli Lilly to acquire cancer drug maker Kelonia in deal worth up to $7 billion https://www.cnbc.com/2026/04/20/eli-lilly-to-acquire-cancer-drug-maker-kelonia.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
GoIrish1776
GoIrish1776 Apr. 12 at 1:59 PM
$MRKR Former senator shines spotlight on a possible breakthrough for pancreatic cancer https://www.cnbc.com/2026/04/10/ben-sasse-shines-spotlight-on-daraxonrasib-for-pancreatic-cancer.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
1 · Reply
johnny6nine
johnny6nine Apr. 9 at 8:43 PM
$MRKR pretty quiet here given the +20% day….. back over $2 soon!
0 · Reply
SinglesOverHomeRun
SinglesOverHomeRun Apr. 9 at 7:40 PM
$MRKR
0 · Reply
stonks_2021
stonks_2021 Apr. 9 at 3:56 PM
$MRKR personally buying here. Seems like the strategic moves are signaling a narrowed time-line to approvals and further products to market.
0 · Reply
stonks_2021
stonks_2021 Apr. 9 at 3:36 PM
https://www.zacks.com/stock/news/2886298/marker-therapeutics-inc-mrkr-reports-q4-loss-tops-revenue-estimates?cid=CS-STOCKTWITS-HL-tale_of_the_tape|yseop_template_4-2886298&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_513_2886298 $MRKR
0 · Reply
itsMeRich
itsMeRich Apr. 9 at 3:26 PM
$MRKR up 20% today- and no one posting????
1 · Reply
itsMeRich
itsMeRich Apr. 9 at 2:10 PM
$MRKR ???
0 · Reply
itsMeRich
itsMeRich Apr. 6 at 1:38 PM
$MRKR Does anyone know the next catalyst that might move this- and when? Other firms cancer treatments seem to be moving along much quicker than this turtle.
0 · Reply